EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors

Ranjit Banwait, Heidi Ko, Joel Michalek, Qianqian Liu, Kate Lathrop, Elizabeth Bowhay-Carnes, Georgios Fotopoulos, John Sarantopoulos, Richard Elledge, Josephine Taverna, Anand Karnad, Kalliopi P Siziopikou und 1 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35446 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Ranjit Banwait und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology Oncology, UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Furans, Ketones, Neoplasms. Die Arbeit nennt 19 Literaturangaben. Gefördert von: EISAI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angiogenesis and resistance mechanisms to anti‐angiogenic therapies were primary motivations for combining these agents. The trial enrolled 29 patients, heavily pretreated with at least three prior lines of chemotherapy, and aimed to assess the efficacy and safety of the combination therapy. Overall response rate (ORR) was 24% with the highest responses observed in breast cancer (29%) and lung cancer (33%) patients. Median progression‐free survival (PFS) was 7.4 months (95% CI 4.5, NA), and overall survival (OS) was 8.2 months (95% CI 6.4 to 14.9). A significant improvement in both OS and PFS was found in vimentin‐negative patients, suggesting that vimentin expression may be a predictor of treatment response. The most common treatment‐related adverse events (TRAEs) were oral mucositis, fatigue, neutropenia, and nausea. Grade ≥3 TRAEs included neutropenia (34.5%), febrile neutropenia (17.2%), and hypertension (13.8%), with one fatal case of sepsis reported. While the study demonstrated the potential of lenvatinib and eribulin in advanced solid tumors, particularly breast and lung cancers, it also highlighted the need for further investigation into biomarkers like vimentin to predict therapeutic outcomes. The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsFuransKetonesNeoplasmsPhenylurea CompoundsQuinolinesAdultAgedFemaleHumansMaleMiddle AgedPilot ProjectsPolyether Polyketides

Stichwörter der Autor:innen

advanced solid tumorsangiogenesis inhibitioneribulinlenvatinibvimentin

Substanzen

eribulinFuransKetoneslenvatinibPhenylurea CompoundsQuinolinesPolyether Polyketides

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology Oncology, UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA.
  • Biostatistics Division, Department of Population Health Sciences, UT Health San Antonio, San Antonio, Texas, USA.
  • Department of Medicine, Division of Pathology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.

ORCID-Profile: Virginia Kaklamani

Förderung

  • EISAI

Zitieren

APA

Banwait, R., Ko, H., Michalek, J., Liu, Q., Lathrop, K., Bowhay-Carnes, E., Fotopoulos, G., Sarantopoulos, J., Elledge, R., Taverna, J., Karnad, A., Siziopikou, K. P., & Kaklamani, V. (2025). Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. International Journal of Cancer. https://doi.org/10.1002/ijc.35446

Vancouver

Banwait R, Ko H, Michalek J, Liu Q, Lathrop K, Bowhay-Carnes E, et al. Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. International Journal of Cancer. 2025. doi:10.1002/ijc.35446

BibTeX
@article{Banwait2025,
  author = {Banwait, Ranjit and Ko, Heidi and Michalek, Joel and Liu, Qianqian and Lathrop, Kate and Bowhay-Carnes, Elizabeth and Fotopoulos, Georgios and Sarantopoulos, John and Elledge, Richard and Taverna, Josephine and Karnad, Anand and Siziopikou, Kalliopi P and Kaklamani, Virginia},
  title = {Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35446}
}
Kostenlos starten →